LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
ELI LILLY & Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1240.34−16.69 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $1.11T
- P/E (TTM)
- 41.6
- Dividend yield
- 0.50%
Share price
+$437.51 (+54.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
ELI LILLY & Co grew revenue 49.6% to $79.67B over the twelve months to Jun 30, 2026.
Revenue
$79.67B
+49.6% vs. a year earlier
EPS, diluted
$29.80
+94.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.11T
- P/E ratio
- 41.6
- Price to sales
- 13.91
- Price to book
- 32.72
- Dividend yield
- 0.50%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $79.67B
- Net income
- $26.71B
- EPS, diluted
- $29.80
- Book value per share
- $37.91
- Diluted shares
- 894M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$79.67B+49.6% YoY
Gross profit
$66.44B+51.0% YoY
Net income
$26.71B+93.6% YoY
EPS, diluted
$29.80+94.8% YoY
Reported periodTrailing twelve months